Abstract
Purpose
Pituitary adenomas give rise to physical and psychological symptoms, which may persist after biochemical cure. Growing attention has been paid to quality of life (QoL) in these patients. We aimed to systematically analyze QoL assessment methods and QoL outcome in these patients.
Methods
We conducted a systematic literature search up to January 2014 in PubMed, Web of Knowledge, PsycInfo and EMBASE.
Results
102 papers assessing QoL in patients with a pituitary adenoma were included. In clinical (original) studies in which QoL was the primary outcome parameter (n = 54), 19 studies combined a generic questionnaire with a disease-specific questionnaire. QoL was found to be impaired in patients with active disease relative to controls, and generally improved during biochemical cure. However, no normalization occurred, with patients with remitted Cushing’s disease demonstrating the smallest improvement. Somatic factors (e.g., hypopituitarism, sleep characteristics), psychological factors (illness perceptions) and health care environment (rural vs. urban) were identified as influencing factors. Intervention studies (predominantly evaluating medical interventions) have been found to improve QoL.
Conclusions
The growing number of studies assessing QoL generally described the negative impact of pituitary adenomas. QoL research in this patient group could be further elaborated by the development of disease-specific questionnaires for prolactinoma and non-functioning adenoma, consequent use of generic and disease-specific questionnaires and using a long-term (longitudinal) follow-up. Surgical and pharmacological interventions improve but not normalize QoL. We postulate that there might be margin for further improvement of QoL, for instance by using psychosocial interventions, in addition to optimal medical treatment.
Similar content being viewed by others
References
Gardner D, Shoback D (2011) Basic and clinical endocrinology, 9th edn. McGrawHill, Singapore, pp 100–101
Pereira AM (2014) Long-term effects of treatment of pituitary adenomas. Handb Clin Neurol 124:361–371
Badia X, Webb SM, Prieto L, Lara N (2004) Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes 2:13
Webb SM, Badia X, Surinach NL (2006) Validity and clinical applicability of the acromegaly Quality of Life Questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol 155:269–277
Webb SM, Prieto L, Badia X, Albareda M, Catala M, Gaztambide S, Lucas T, Paramo C, Pico A, Lucas A, Halperin I, Obiols G, Astorga R (2002) Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 57:251–258
Rosilio M, Blum WF, Edwards DJ, Shavrikova EP, Valle D, Lamberts SW, Erfurth EM, Webb SM, Ross RJ, Chihara K, Henrich G, Herschbach P, Attanasio AF (2004) Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab 89:1684–1693
McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L, Wiren L (1999) The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 8:373–383
Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, van Aken MO, Pivonello R, Stalla G, Lamberts SW, Glusman JE (2008) Evaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaire. Eur J Endocrinol 158:623–630
Milian M, Teufel P, Honegger J, Gallwitz B, Schnauder G, Psaras T (2012) The development of the Tuebingen Cushing’s disease quality of life inventory (Tuebingen CD-25). Part II: normative data from 1784 healthy people. Clin Endocrinol (Oxf) 76:861–867
Milian M, Teufel P, Honegger J, Gallwitz B, Schnauder G, Psaras T (2012) The development of the Tuebingen Cushing’s disease quality of life inventory (Tuebingen CD-25). Part I: construction and psychometric properties. Clin Endocrinol (Oxf) 76:851–860
French D, Vedhara K, Kaptein AA, Weinman J (2010) Health psychology, 2nd edn. BPS Blackwell, Chichester
Bowling A (2001) Measuring disease. Open University Press, Maidenhead, p 16–18
Schipper H, Clinch JJ, Olweny CLM (1990) Quality of life studies: definitions and conceptual issues. In: Spilker B (ed) Quality of life assessments in clinical trials. Raven Press Ltd, New York, p 16
Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ (2005) Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab 90:3337–3341
Paisley AN, Rowles SV, Roberts ME, Webb SM, Badia X, Prieto L, Shalet SM, Trainer PJ (2007) Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol (Oxf) 67:358–362
Badia X, Roset M, Valassi E, Franz H, Forsythe A, Webb SM (2013) Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing’s syndrome (ERCUSYN). Qual Life Res 22:2941–2950
Nelson LM, Forsythe A, McLeod L, Pulgar S, Maldonado M, Coles T, Zhang Y, Webb SM, Badia X (2013) Psychometric evaluation of the Cushing’s Quality-of-Life questionnaire. Patient 6:113–124
Roset M, Badia X, Forsythe A, Webb SM (2013) Mapping CushingQoL scores onto SF-6D utility values in patients with Cushing’s syndrome. Patient 6:103–111
Santos A, Resmini E, Martinez-Momblan MA, Crespo I, Valassi E, Roset M, Badia X, Webb SM (2012) Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice. Eur J Endocrinol 167:337–342
Milian M, Honegger J, Teufel P, Wolf A, Psaras T (2013) Tuebingen CD-25 is a sensitive tool to investigate health-related quality of life in Cushing’s disease patients in the course of the disease. Neuroendocrinology 98:188–199
Barkan AL (2001) The “quality of life-assessment of growth hormone deficiency in adults” questionnaire: can it be used to assess quality of life in hypopituitarism? J Clin Endocrinol Metab 86:1905–1907
Lenderking WR, Zacker C, Katznelson L, Vance ML, Hossain S, Tafesse E, Guacaneme AO, Pashos CL (2000) The reliability and validity of the impact on lifestyle questionnaire in patients with acromegaly. Value Health 3:261–269
Tiemensma J, Daskalakis NP, van der Veen EM, Ramondt S, Richardson SK, Broadbent E, Romijn JA, Pereira AM, Biermasz NR, Kaptein AA (2012) Drawings reflect a new dimension of the psychological impact of long-term remission of Cushing’s syndrome. J Clin Endocrinol Metab 97:3123–3131
Sippel RS, Elaraj DM, Kebebew E, Lindsay S, Tyrrell JB, Duh QY (2008) Waiting for change: symptom resolution after adrenalectomy for Cushing’s syndrome. Surgery 144:1054–1060
Pikkarainen L, Sane T, Reunanen A (1999) The survival and well-being of patients treated for Cushing’s syndrome. J Intern Med 245:463–468
Nagesser SK, van Seters AP, Kievit J, Hermans J, Krans HM, van de Velde CJ (2000) Long-term results of total adrenalectomy for Cushing’s disease. World J Surg 24:108–113
Kars M, van der Klaauw AA, Onstein CS, Pereira AM, Romijn JA (2007) Quality of life is decreased in female patients treated for microprolactinoma. Eur J Endocrinol 157:133–139
Cesar de Oliveira NE, Violante AHD, Caldas D, Lamounier FA, Rezende LC, Fontes R, Schrank Y, de Gomes SR, Vaisman M, Guerra E, Sebastian A, Colao A (2008) Quality of life in women with microprolactinoma treated with dopamine agonists. Pituitary 11:247–254
Sonino N, Ruini C, Navarrini C, Ottolini F, Sirri L, Paoletta A, Fallo F, Boscaro M, Fava GA (2007) Psychosocial impairment in patients treated for pituitary disease: a controlled study. Clin Endocrinol 67:719–726
Raappana A, Pirila T, Ebeling T, Salmela P, Sintonen H, Koivukangas J (2012) Long-term health-related quality of life of surgically treated pituitary adenoma patients: a descriptive study. ISRN Endocrinol 2012:675310
Johnson MD, Woodburn CJ, Vance ML (2003) Quality of life in patients with a pituitary adenoma. Pituitary 6:81–87
Dekkers OM, van der Klaauw AA, Pereira AM, Biermasz NR, Honkoop PJ, Roelfsema F, Smit JW, Romijn JA (2006) Quality of life is decreased after treatment for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 91:3364–3369
Biermasz NR, Joustra SD, Donga E, Pereira AM, van Duinen N, van Dijk M, van der Klaauw AA, Corssmit EP, Lammers GJ, van Kralingen KW, van Dijk JG, Romijn JA (2011) Patients previously treated for nonfunctioning pituitary macroadenomas have disturbed sleep characteristics, circadian movement rhythm, and subjective sleep quality. J Clin Endocrinol Metab 96:1524–1532
Capatina C, Christodoulides C, Fernandez A, Cudlip S, Grossman AB, Wass JA, Karavitaki N (2013) Current treatment protocols can offer a normal or near-normal quality of life in the majority of patients with non-functioning pituitary adenomas. Clin Endocrinol (Oxf) 78:86–93
Nielsen EH, Lindholm J, Laurberg P, Bjerre P, Christiansen JS, Hagen C, Juul S, Jorgensen J, Kruse A, Stochholm K (2007) Nonfunctioning pituitary adenoma: incidence, causes of death and quality of life in relation to pituitary function. Pituitary 10:67–73
Page RC, Hammersley MS, Burke CW, Wass JA (1997) An account of the quality of life of patients after treatment for non-functioning pituitary tumours. Clin Endocrinol (Oxf) 46:401–406
Casanueva FF, Leal A, Koltowska-Haggstrom M, Jonsson P, Goth MI (2005) Traumatic brain injury as a relevant cause of growth hormone deficiency in adults: a KIMS-based study. Arch Phys Med Rehabil 86:463–468
Kreitschmann-Andermahr I, Poll EM, Reineke A, Gilsbach JM, Brabant G, Buchfelder M, Fassbender W, Faust M, Kann PH, Wallaschofski H (2008) Growth hormone deficient patients after traumatic brain injury—baseline characteristics and benefits after growth hormone replacement—an analysis of the German KIMS database. Growth Horm IGF Res 18:472–478
Verhelst J, Kendall-Taylor P, Erfurth EM, Price DA, Geffner M, Koltowska-Haggstrom M, Jonsson PJ, Wilton P, Abs R (2005) Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab 90:4636–4643
Mattoo SK, Bhansali AK, Gupta N, Grover S, Malhotra R (2008) Psychosocial morbidity in acromegaly: a study from India. Endocrine 34:17–22
Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, Romijn JA, Roelfsema F (2004) Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89:5369–5376
Psaras T, Milian M, Hattermann V, Will BE, Tatagiba M, Honegger J (2011) Predictive factors for neurocognitive function and quality of life after surgical treatment for Cushing’s disease and acromegaly. J Endocrinol Invest 34:e168–e177
Kauppinen-Makelin R, Sane T, Sintonen H, Markkanen H, Valimaki MJ, Loyttyniemi E, Niskanen L, Reunanen A, Stenman UH (2006) Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab 91:3891–3896
Celik O, Hatipoglu E, Akhan SE, Uludag S, Kadioglu P (2013) Acromegaly is associated with higher frequency of female sexual dysfunction: experience of a single center. Endocr J 60:753–761
Leon-Carrion J, Martin-Rodriguez JF, Madrazo-Atutxa A, Soto-Moreno A, Venegas-Moreno E, Torres-Vela E, Benito-Lopez P, Galvez MA, Tinahones FJ, Leal-Cerro A (2010) Evidence of cognitive and neurophysiological impairment in patients with untreated naive acromegaly. J Clin Endocrinol Metab 95:4367–4379
Feldt-Rasmussen U, Abs R, Bengtsson BA, Bennmarker H, Bramnert M, Hernberg-Stahl E, Monson JP, Westberg B, Wilton P, Wuster C (2002) Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing’s disease. Eur J Endocrinol 146:67–74
Valassi E, Brick DJ, Johnson JC, Biller BM, Klibanski A, Miller KK (2012) Effect of growth hormone replacement therapy on the quality of life in women with growth hormone deficiency who have a history of acromegaly versus other disorders. Endocr Pract 18:209–218
van der Pas R, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, de Jong FH, van der Lely AJ, de Herder WW, Webb SM, Lamberts SW, Hofland LJ, Feelders RA (2012) Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing’s disease. Pituitary 16:536–544
Mattoo SK, Bhansali AK, Gupta N, Grover S, Malhotra R (2009) Psychosocial morbidity in Cushing disease: a study from India. Endocrine 35:306–311
Ding XF, Li HZ, Yan WG, Gao Y, Li XQ (2010) Role of adrenalectomy in recurrent Cushing’s disease. Chin Med J (Engl) 123:1658–1662
Hawn MT, Cook D, Deveney C, Sheppard BC (2002) Quality of life after laparoscopic bilateral adrenalectomy for Cushing’s disease. Surgery 132:1064–1068
Alcalar N, Ozkan S, Kadioglu P, Celik O, Cagatay P, Kucukyuruk B, Gazioglu N (2012) Evaluation of depression, quality of life and body image in patients with Cushing’s disease. Pituitary 16:333–340
Lindsay JR, Nansel T, Baid S, Gumowski J, Nieman LK (2006) Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J Clin Endocrinol Metab 91:447–453
van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW, Roelfsema F, Lamberts SW, Romijn JA (2005) Quality of life in patients after long-term biochemical cure of Cushing’s disease. J Clin Endocrinol Metab 90:3279–3286
Sonino N, Bonnini S, Fallo F, Boscaro M, Fava GA (2006) Personality characteristics and quality of life in patients treated for Cushing’s syndrome. Clin Endocrinol (Oxf) 64:314–318
Smith PW, Turza KC, Carter CO, Vance ML, Laws ER, Hanks JB (2009) Bilateral adrenalectomy for refractory Cushing disease: a safe and definitive therapy. J Am Coll Surg 208:1059–1064
Wagenmakers MA, Netea-Maier RT, Prins JB, Dekkers T, den Heijer M, Hermus AR (2012) Impaired quality of life in patients in long-term remission of Cushing’s syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism? Eur J Endocrinol 167:687–695
Lindholm J, Juul S, Jorgensen JOL, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen LO, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86:117–123
Abraham SB, Abel BS, Rubino D, Nansel T, Ramsey S, Nieman LK (2013) A direct comparison of quality of life in obese and Cushing’s syndrome patients. Eur J Endocrinol 168:787–793
Hoybye C, Ragnarsson O, Jonsson PJ, Koltowska-Haggstrom M, Trainer P, Feldt-Rasmussen U, Biller BM (2010) Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing’s disease. Eur J Endocrinol 162:677–684
Thompson SK, Hayman AV, Ludlam WH, Deveney CW, Loriaux DL, Sheppard BC (2007) Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing’s disease: a 10-year experience. Ann Surg 245:790–794
Milian M, Honegger J, Gerlach C, Psaras T (2013) Health-related quality of life and psychiatric symptoms improve effectively within a short time in patients surgically treated for pituitary tumors—a longitudinal study of 106 patients. Acta Neurochir (Wien) 155:1637–1645
Heald AH, Ghosh S, Bray S, Gibson C, Anderson SG, Buckler H, Fowler HL (2004) Long-term negative impact on quality of life in patients with successfully treated Cushing’s disease. Clin Endocrinol (Oxf) 61:458–465
van der Klaauw AA, Kars M, Biermasz NR, Roelfsema F, Dekkers OM, Corssmit EP, van Aken MO, Havekes B, Pereira AM, Pijl H, Smit JW, Romijn JA (2008) Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin Endocrinol (Oxf) 69:775–784
Baird A, Sullivan T, Zafar S, Rock J (2003) Quality of life in patients with pituitary tumors: a preliminary study. Qual Manag Health Care 12:97–105
Pereira-Neto A, Borba AM, Mello PA, Naves LA, Araujo AS Jr, Casulari LA (2010) Mean intrasellar pressure, visual field, headache intensity and quality of life of patients with pituitary adenoma. Arq Neuropsiquiatr 68:350–354
Van der Zee KI, Sanderman R 2012 Het meten van de algemene gezondheidstoestand met de RAND-36, een handleiding (Manual SF-36, in Dutch). Noordelijk Centrum voor Gezondheidvraagstukken. Groningen, Rijks Universiteit Groningen
Hopman WM, Towheed T, Anastassiades T, Tenenhouse A, Poliquin S, Berger C, Joseph L, Brown JP, Murray TM, Adachi JD, Hanley DA, Papadimitropoulos E (2000) Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group. CMAJ 163:265–271
Loge JH, Kaasa S (1998) Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med 26:250–258
Jorngarden A, Wettergen L, von EL (2006) Measuring health-related quality of life in adolescents and young adults: Swedish normative data for the SF-36 and the HADS, and the influence of age, gender, and method of administration. Health Qual Life Outcomes 4:91
Blake C, Codd MB, O’Meara YM (2000) The short form 36 (SF-36) health survey: normative data for the Irish population. Ir J Med Sci 169:195–200
Cruz LN, Fleck MP, Oliveira MR, Camey SA, Hoffmann JF, Bagattini AM, Polanczyk CA (2013) Health-related quality of life in Brazil: normative data for the SF-36 in a general population sample in the south of the country. Cien Saude Colet 18:1911–1921
Tanemura E, Nagatani T, Aimi Y, Kishida Y, Takeuchi K, Wakabayashi T (2012) Quality of life in nonfunctioning pituitary macroadenoma patients before and after surgical treatment. Acta Neurochir (Wien) 154:1895–1902
van der Klaauw AA, Dekkers OM, Pereira AM, van Kralingen KW, Romijn JA (2007) Increased daytime somnolence despite normal sleep patterns in patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92:3898–3903
van Beek AP, van den Bergh AC, van den Berg LM, van den Berg G, Keers JC, Langendijk JA, Wolffenbuttel BH (2007) Radiotherapy is not associated with reduced quality of life and cognitive function in patients treated for nonfunctioning pituitary adenoma. Int J Radiat Oncol Biol Phys 68:986–991
Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM, Christ ER (2005) Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin Endocrinol (Oxf) 63:103–110
Sardella C, Lombardi M, Rossi G, Cosci C, Brogioni S, Scattina I, Webb SM, Gasperi M, Martino E, Bogazzi F (2010) Short- and long-term changes of quality of life in patients with acromegaly: results from a prospective study. J Endocrinol Invest 33:20–25
Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P (2008) Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 158:305–310
Wexler T, Gunnell L, Omer Z, Kuhlthau K, Beauregard C, Graham G, Utz AL, Biller B, Nachtigall L, Loeffler J, Swearingen B, Klibanski A, Miller KK (2009) Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab 94:2471–2477
Bonapart IE, van Domburg R, ten Have SM, de Herder WW, Erdman RA, Janssen JA, van der Lely AJ (2005) The ‘bio-assay’ quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. Eur J Endocrinol 152:217–224
Celik O, Kadioglu P (2012) Quality of life in female patients with acromegaly. J Endocrinol Invest 36:412–416
Hua SC, Yan YH, Chang TC (2006) Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol 155:831–837
T’Sjoen G, Bex M, Maiter D, Velkeniers B, Abs R (2007) Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. Eur J Endocrinol 157:411–417
Cannavo S, Condurso R, Ragonese M, Ferrau F, Alibrandi A, Arico I, Romanello G, Squadrito S, Trimarchi F, Silvestri R (2011) Increased prevalence of restless legs syndrome in patients with acromegaly and effects on quality of life assessed by Acro-QoL. Pituitary 14:328–334
Wassenaar MJ, Biermasz NR, Kloppenburg M, van der Klaauw AA, Tiemensma J, Smit JW, Pereira AM, Roelfsema F, Kroon HM, Romijn JA (2010) Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. Growth Horm IGF Res 20:226–233
Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90:2731–2739
Miller A, Doll H, David J, Wass J (2008) Impact of musculoskeletal disease on quality of life in long-standing acromegaly. Eur J Endocrinol 158:587–593
Psaras T, Honegger J, Gallwitz B, Milian M (2011) Are there gender-specific differences concerning quality of life in treated acromegalic patients? Exp Clin Endocrinol Diabetes 119:300–305
Yamada S, Fukuhara N, Nishioka H, Takeshita A, Suzuki H, Miyakawa M, Takeuchi Y (2011) GH deficiency in patients after cure of acromegaly by surgery alone. Eur J Endocrinol 165:873–879
Fujio S, Tokimura H, Hirano H, Hanaya R, Kubo F, Yunoue S, Bohara M, Kinoshita Y, Tominaga A, Arimura H, Arita K (2013) Severe growth hormone deficiency is rare in surgically-cured acromegalics. Pituitary 16:326–332
van der Klaauw AA, Biermasz NR, Hoftijzer HC, Pereira AM, Romijn JA (2008) Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. Clin Endocrinol (Oxf) 69:123–128
Postma MR, Netea-Maier RT, van den Berg G, Homan J, Sluiter WJ, Wagenmakers MA, van den Bergh AC, Wolffenbuttel BH, Hermus AR, van Beek AP (2012) Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. Eur J Endocrinol 166:585–592
Rubeck KZ, Madsen M, Andreasen CM, Fisker S, Frystyk J, Jorgensen JOL (2010) Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. Eur J Endocrinol 163:717–726
Siegel S, Streetz-van der Werf C, Schott JS, Nolte K, Karges W, Kreitschmann-Andermahr I (2012) Diagnostic delay is associated with psychosocial impairment in acromegaly. Pituitary 16:507–514
Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR (2011) Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. J Clin Endocrinol Metab 96:3550–3558
Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, Wass JA, Chabre O, Pfeifer M, Feelders RA, Tsagarakis S, Trainer PJ, Franz H, Zopf K, Zacharieva S, Lamberts SW, Tabarin A, Webb SM (2011) The European registry on Cushing’s syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 165:383–392
Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR (2011) Negative illness perceptions are associated with impaired quality of life in patients after long-term remission of Cushing’s syndrome. Eur J Endocrinol 165:527–535
Sonino N, Scarpa E, Paoletta A, Fallo F, Boscaro M (1999) Slow-release lanreotide treatment in acromegaly: effects on quality of life. Psychother Psychosom 68:165–167
Lombardi G, Minuto F, Tamburrano G, Ambrosio MR, Arnaldi G, Arosio M, Chiarini V, Cozzi R, Grottoli S, Mantero F, Bogazzi F, Terzolo M, Tita P, Boscani PF, Colao A (2009) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest 32:202–209
Mangupli R, Camperos P, Webb SM (2013) Biochemical and quality of life responses to octreotide-LAR in acromegaly. Pituitary 17:495–499
Karaca Z, Tanriverdi F, Elbuken G, Cakir I, Donmez H, Selcuklu A, Durak AC, Dokmetas HS, Colak R, Unluhizarci K, Kelestimur F (2011) Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly. Clin Endocrinol (Oxf) 75:678–684
Ghigo E, Biller BM, Colao A, Kourides IA, Rajicic N, Hutson RK, De ML, Klibanski A (2009) Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. J Endocrinol Invest 32:924–933
Trainer PJ, Ezzat S, D’Souza GA, Layton G, Strasburger CJ (2009) A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol 71:549–557
Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93:3853–3859
Madsen M, Poulsen PL, Orskov H, Moller N, Jorgensen JO (2011) Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab 96:2405–2413
Schopohl J, Strasburger CJ, Caird D, Badenhoop K, Beuschlein F, Droste M, Plockinger U, Petersenn S (2011) Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes 119:156–162
Biermasz NR, van den Oever NC, Frolich M, Arias AM, Smit JW, Romijn JA, Roelfsema F (2003) Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol (Oxf) 58:288–295
Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab 97:2039–2049
Katznelson L, Loriaux DL, Feldman D, Braunstein GD, Schteingart DE, Gross C (2013) Global clinical response in Cushing’s syndrome patients treated with mifepristone. Clin Endocrinol (Oxf) 80:562–569
Giavoli C, Profka E, Verrua E, Ronchi CL, Ferrante E, Bergamaschi S, Sala E, Malchiodi E, Lania AG, Arosio M, Ambrosi B, Spada A, Beck-Peccoz P (2012) GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency. J Clin Endocrinol Metab 97:3983–3988
Svensson J, Finer N, Bouloux P, Bevan J, Jonsson B, Mattsson AF, Lundberg M, Harris PE, Koltowska-Haggstrom M, Monson JP (2007) Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical response. Growth Horm IGF Res 17:67–76
van der Klaauw AA, Bax JJ, Roelfsema F, Stokkel MP, Bleeker GB, Biermasz NR, Smit JW, Romijn JA, Pereira AM (2009) Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly. Pituitary 12:339–346
Miller KK, Wexler T, Fazeli P, Gunnell L, Graham GJ, Beauregard C, Hemphill L, Nachtigall L, Loeffler J, Swearingen B, Biller BM, Klibanski A (2010) Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab 95:567–577
Hatipoglu E, Topsakal N, Atilgan OE, Alcalar N, Camliguney AF, Niyazoglu M, Cotuk HB, Kadioglu P (2013) Impact of exercise on quality of life and body-self perception of patients with acromegaly. Pituitary 17:38–43
Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD (2001) Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 119:1050–1058
Kay S, Ferreira A (2014) Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores. Ophthalmic Epidemiol 21:66–78
Bandura A (1997) Self-efficacy: the exercise of control. Freeman, New York
Haugland T, Veenstra M, Vatn MH, Wahl AK (2013) Improvement in stress, general self-efficacy, and health related quality of life following patient education for patients with neuroendocrine tumors: a pilot study. Nurs Res Pract 2013:695820
Gardner DG, Shoback D (2011) Basic & clinical endocrinology, 9th edn. McGrawHill, Singapore, pp 101–102
Kvistborg A, Halse J, Bakke S, Bjoro T, Hansen E, Djoseland O, Brownell J, Jervell J (1993) Long-term treatment of macroprolactinomas with CV 205-502. Acta Endocrinol (Copenh) 128:301–307
Reavley A, Fisher AD, Owen D, Creed FH, Davis JR (1997) Psychological distress in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 47:343–348
Sievers C, Ising M, Pfister H, Dimopoulou C, Schneider HJ, Roemmler J, Schopohl J, Stalla GK (2009) Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls. Eur J Endocrinol 160:367–373
Sievers C, Dimopoulou C, Pfister H, Lieb R, Steffin B, Roemmler J, Schopohl J, Mueller M, Schneider HJ, Ising M, Wittchen HU, Stalla GK (2009) Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients. Clin Endocrinol 71:691–701
Tiemensma J, Biermasz NR, van der Mast RC, Wassenaar MJE, Middelkoop HAM, Pereira AM, Romijn JA (2010) Increased psychopathology and maladaptive personality traits, but normal cognitive functioning, in patients after long-term cure of acromegaly. J Clin Endocrinol Metab 95:E392–E402
Tiemensma J, Biermasz NR, Middelkoop HAM, van der Mast RC, Romijn JA, Pereira AM (2010) Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing’s disease. J Clin Endocrinol Metab 95:E129–E141
Sievers C, Brubach K, Saller B, Schneider HJ, Buchfelder M, Droste M, Mann K, Strasburger CJ, Stalla GK (2010) Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS). Clin Endocrinol (Oxf) 73:89–94
Andela CD, Niemeijer ND, Scharloo M, Tiemensma J, Kanagasabapathy S, Pereira AM, Kamminga NG, Kaptein AA, Biermasz NR (2014) Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL. Pituitary. doi:10.1007/s11102-014-0561-1
Caglar E, Hatipoglu E, Niyazoglu M, Celik O, Tuncer M, Kadioglu P (2013) Acromegaly is not associated with irritable bowel syndrome: a pilot study. Neuro Endocrinol Lett 34:71–74
Acknowledgments
We thank research intern Aurelie Girbes for her contribution to this review and Jan W. Schoones for his contribution to the literature search.
Conflict of interest
The authors have nothing to disclose.
Author information
Authors and Affiliations
Corresponding author
Appendices
Appendix 1: Search strategy
PubMed
(“Pituitary Neoplasms”[mesh] OR “Pituitary Neoplasms”[all fields] OR “Pituitary Neoplasm”[all fields] OR “Pituitary Tumors”[all fields] OR “Pituitary Tumor”[all fields] OR “Pituitary Adenomas”[all fields] OR “Pituitary Adenomas”[all fields] OR “ACTH-Secreting Pituitary Adenoma”[all fields] OR “ACTH-Secreting Pituitary Adenomas”[all fields] OR “Corticotroph Adenoma”[all fields] OR “Corticotroph Adenomas”[all fields] OR “Cushing syndrome”[mesh] OR “Cushing syndrome”[all fields] OR “Cushing’s Syndrome”[all fields] OR “Hypercortisolism”[all fields] OR “Cushing disease”[all fields] OR “Cushing’s disease”[all fields] OR “Growth Hormone-Secreting Pituitary Adenoma”[all fields] OR “Growth Hormone-Secreting Pituitary Adenomas”[all fields] OR “Acromegaly”[all fields] OR “Prolactinoma”[all fields] OR “Prolactinomas”[all fields] OR “Microprolactinoma”[all fields] OR “Microprolactinomas”[all fields] OR “Macroprolactinoma”[all fields] OR “Macroprolactinomas”[all fields] OR “non-functioning adenoma”[all fields] OR “non-functioning adenomas”[all fields] OR “non-functioning pituitary adenoma”[all fields] OR “non-functioning pituitary adenomas”[all fields] OR “non-functioning macroadenoma”[all fields] OR “non-functioning macroadenomas”[all fields] OR “nonfunctioning adenoma”[all fields] OR “nonfunctioning adenomas”[all fields] OR “nonfunctioning pituitary adenoma”[all fields] OR “nonfunctioning pituitary adenomas”[all fields] OR “nonfunctioning pituitary macroadenoma”[all fields] OR “nonfunctioning pituitary macroadenomas”[all fields] OR “nonfunctioning macroadenoma”[all fields] OR “nonfunctioning macroadenomas”[all fields]) AND (“quality of life”[mesh] OR “quality of life”[all fields] OR “life quality”[all fields] OR “qol”[all fields] OR “daily functioning”[all fields] OR “daily routine”[all fields] OR “health related quality of life”[all fields] OR “well-being”[all fields] OR “wellbeing”[all fields]).
PsycINFO
(“Pituitary Neoplasms” OR “Pituitary Neoplasms” OR “Pituitary Neoplasm” OR “Pituitary Tumors” OR “Pituitary Tumor” OR “Pituitary Adenomas” OR “Pituitary Adenomas” OR “ACTH-Secreting Pituitary Adenoma” OR “ACTH-Secreting Pituitary Adenomas” OR “Pituitary Corticotropin-Secreting Adenoma” OR “Pituitary Corticotropin-Secreting Adenomas” OR “Corticotroph Adenoma” OR “Corticotroph Adenomas” OR “Growth Hormone-Secreting Pituitary Adenoma” OR “Growth Hormone-Secreting Pituitary Adenomas” OR “Pituitary Growth Hormone Secreting Adenoma” OR “Pituitary Growth Hormone Secreting Adenomas” OR “Prolactinoma” OR “Prolactinomas” OR “Microprolactinoma” OR “Microprolactinomas” OR “Macroprolactinoma” OR “Macroprolactinomas” OR “Acromegaly” OR “non-functioning adenoma” OR “non-functioning adenomas” OR “non-functioning macroadenoma” OR “non-functioning macroadenomas” OR “nonfunctioning adenoma” OR “nonfunctioning adenomas” OR “nonfunctioning pituitary adenoma” OR “nonfunctioning pituitary adenomas” OR “nonfunctioning pituitary macroadenoma” OR “nonfunctioning pituitary macroadenomas” OR “nonfunctioning macroadenoma” OR “nonfunctioning macroadenomas” OR “Cushing syndrome” OR “Cushing syndrome” OR “Cushing’s Syndrome” OR “Hypercortisolism” OR “Cushing disease” OR “Cushing’s disease” OR “Cushings Syndrome” OR “Hypothalamic Pituitary Adrenal Axis” OR “Hypopituitarism” OR “Pituitary Disorders” OR “Hypopituitarism”) AND (“Quality of Life” OR “Quality of Work Life” OR “Relationship Quality” OR “Family Relations” OR “Life Changes” OR “Life Experiences” OR “Lifestyle” OR “Spirituality” OR “quality of life” OR “quality of life” OR “life quality” OR “qol” OR “daily functioning” OR “daily routine” OR “limitations of functioning” OR “health related quality of life” OR “quality of life” OR “quality of life” OR “life quality” OR “qol” OR “daily functioning” OR “daily routine” OR “limitations of functioning” OR “health related quality of life” OR “well-being” OR “wellbeing”).
Web of science
TS = (Pituitary Neoplasms OR Pituitary Neoplasm OR Pituitary Tumors OR Pituitary Tumor OR Pituitary Adenomas OR Pituitary Adenomas OR ACTH-Secreting Pituitary Adenoma OR ACTH-Secreting Pituitary Adenomas OR Corticotroph Adenoma OR Corticotroph Adenomas OR Cushing syndrome OR Cushing syndrome OR Cushing’s Syndrome OR Hypercortisolism OR Cushing disease OR Cushing’s disease OR Growth Hormone-Secreting Pituitary Adenoma OR Growth Hormone-Secreting Pituitary Adenomas OR Prolactinoma OR Prolactinomas OR Microprolactinoma OR Microprolactinomas OR Macroprolactinoma OR Macroprolactinomas OR Acromegaly OR non-functioning adenoma OR non-functioning adenomas OR non-functioning macroadenoma OR non-functioning macroadenomas OR nonfunctioning adenoma OR nonfunctioning adenomas OR nonfunctioning pituitary adenoma OR nonfunctioning pituitary adenomas OR nonfunctioning pituitary macroadenoma OR nonfunctioning pituitary macroadenomas OR nonfunctioning macroadenoma OR nonfunctioning macroadenomas OR Cushing syndrome OR Cushing syndrome OR Cushing’s Syndrome OR Hypercortisolism OR Cushing disease OR Cushing’s disease) AND TS = (quality of life OR quality of life OR life quality OR qol OR daily functioning OR daily routine OR health related quality of life OR well-being OR wellbeing).
Embase
(exp hypophysis tumor/OR “Pituitary Neoplasms”.mp OR “Pituitary Neoplasm”.mp OR “Pituitary Tumors”.mp OR “Pituitary Tumor”.mp OR “Pituitary Adenomas”.mp OR “Pituitary Adenomas”.mp OR “ACTH-Secreting Pituitary Adenoma”.mp OR “ACTH-Secreting Pituitary Adenomas”.mp OR “Corticotroph Adenoma”.mp OR “Corticotroph Adenomas”.mp OR Cushing syndrome/OR “Cushing syndrome”.mp OR “Cushing’s Syndrome”.mp OR “Hypercortisolism”.mp OR “Cushing disease”.mp OR “Cushing’s disease”.mp OR “Growth Hormone-Secreting Pituitary Adenoma”.mp OR “Growth Hormone-Secreting Pituitary Adenomas”.mp OR “Acromegaly”.mp OR “Prolactinoma”.mp OR “Prolactinomas”.mp OR “Microprolactinoma”.mp OR “Microprolactinomas”.mp OR “Macroprolactinoma”.mp OR “Macroprolactinomas”.mp OR “non-functioning adenoma”.mp OR “non-functioning adenomas”.mp OR “non-functioning pituitary adenoma”.mp OR “non-functioning pituitary adenomas”.mp OR “non-functioning macroadenoma”.mp OR “non-functioning macroadenomas”.mp OR “nonfunctioning adenoma”.mp OR “nonfunctioning adenomas”.mp OR “nonfunctioning pituitary adenoma”.mp OR “nonfunctioning pituitary adenomas”.mp OR “nonfunctioning pituitary macroadenoma”.mp OR “nonfunctioning pituitary macroadenomas”.mp OR “nonfunctioning macroadenoma”.mp OR “nonfunctioning macroadenomas”.mp) AND (exp “quality of life”/OR “quality of life”.mp OR “life quality”.mp OR “qol”.mp OR “daily functioning”.mp OR “daily routine”.mp OR “health related quality of life”.mp OR “well-being”.mp OR “wellbeing”.mp).
Appendix 2: Spider plot data
PF: Physical functioning, PR: Physical role, GH: General health, Vit: Vitality, SF: Social functioning, ER: Emotional role, MH: Mental health
Dutch a-select sample (67)
PF | PR | Pain | GH | Vit | SF | ER | MH | |
---|---|---|---|---|---|---|---|---|
Average score | 81.9 | 79.4 | 79.5 | 72.7 | 67.4 | 86.9 | 84.1 | 76.8 |
Prolactinoma
Active/naïve patient groups
PF | PR | Pain | GH | Vit | SF | ER | MH | |
---|---|---|---|---|---|---|---|---|
Johnson et al. [31] | 49.3 | 46.2 | 47.9 | 47 | 43.8 | 41.3 | 40.3 | 43.8 |
Average score | 49.3 | 46.2 | 47.9 | 47 | 43.8 | 41.3 | 40.3 | 43.8 |
Controlled/treated patient groups
NFA
Active/naïve patient groups
PF | PR | Pain | GH | Vit | SF | ER | MH | |
---|---|---|---|---|---|---|---|---|
Johnson et al. [31] | 45.9 | 43 | 46.2 | 46.4 | 40.9 | 41.7 | 41.2 | 44.8 |
Average score | 45.9 | 43 | 46.2 | 46.4 | 40.9 | 41.7 | 41.2 | 44.8 |
Controlled/treated patient groups
PF | PR | Pain | GH | Vit | SF | ER | MH | |
---|---|---|---|---|---|---|---|---|
Biermasz et al. [33] (remission) | 85.6 | 76.5 | 87.8 | 68.4 | 89.0 | 90.2 | ||
Dekkers et al. [32] (remission) | 79.0 | 65 | 81.3 | 57.3 | 79.0 | 69.1 | ||
Page et al. [36] (treated) | 79 | 73 | 80 | 66 | 57 | 86 | 78 | 75 |
Nielsen et al. [35] (treated) | 84 | 72.4 | 82.8 | 70.1 | 66.3 | 90.6 | 77.5 | 82.3 |
Van Beek et al. [75] (RT +) | 84 | 76 | 84 | 60 | 66 | 85 | 88 | 79 |
Van Beek et al. [75] (RT-) | 74 | 69 | 81 | 59 | 56 | 77 | 78 | 72 |
Capatina et al. [34] (treated) | 71.5 | 64.5 | 75.3 | 62.1 | 55.0 | 79.1 | 75.9 | 76.6 |
Miller et al. [87] (after GH therapy) | 85.4 | 98.1 | 78.1 | 76.8 | 61.5 | 96.2 | 92.3 | 85.2 |
Miller et al. [87] (after placebo) | 63.9 | 62.5 | 61.1 | 48.6 | 46.1 | 67 | 57.1 | 66.3 |
Average score | 78.5 | 73.0 | 79.0 | 63.1 | 58.3 | 83.2 | 78.5 | 76.6 |
Acromegaly
Active/naïve patients
Controlled/treated patient groups
PF | PR | Pain | GH | Vit | SF | ER | MH | |
---|---|---|---|---|---|---|---|---|
Miller et al. [113] (after GH therapy) | 85.4 | 98.1 | 78.1 | 76.8 | 61.5 | 96.2 | 92.3 | 85.2 |
Miller et al. [113] (after placebo) | 63.9 | 62.5 | 61.1 | 48.6 | 46.1 | 67 | 57.1 | 66.3 |
Wassenaar et al. [85] (spine OA) | 72.6 | 58.9 | 67.1 | 54.4 | 77.2 | 62 | ||
Wassenaar et al. [85] (no spine OA) | 84.7 | 90 | 86.9 | 72.7 | 93.3 | 95.5 | ||
Van der Klaauw et al. [91] (follow-up) | 72.1 | 67.4 | 72.6 | 59.9 | 79 | 75.1 | ||
Wexler et al. [79] (GHD) | 72 | 68 | 64.9 | 55.2 | 38.4 | 74.5 | 72 | 66.7 |
Wexler et al. [79] (GH sufficient) | 94.4 | 100 | 84.6 | 78.3 | 66.8 | 95.8 | 100 | 78.2 |
Biermasz et al. [41] (remission) | 68.6 | 57.4 | 72.2 | 55.6 | 79.6 | 70.3 | ||
Biermasz et al. [86] (no joint problems) | 83.9 | 76.9 | 92 | 70.6 | 88 | 84 | ||
Biermasz et al. [86] (joint problems) | 64 | 51.7 | 66.3 | 51.2 | 77.1 | 66.3 | ||
Postma et al. [92] (SSTA +) | 65 | 46 | 65 | 49 | 48 | 66 | 78 | 72 |
Postma et al. [92] (SSTA-) | 79 | 65 | 78 | 63 | 58 | 75 | 75 | 75 |
Milian et al. [62] (12 months after surgery) | 51.1 | 54.3 | 36.5 | 46.7 | 52.2 | 55.8 | 56.7 | 60.5 |
Miller et al. [87] (controlled) | 65 | 65.7 | 60.7 | 55.4 | 51 | 76.9 | 76.6 | 73 |
Psaras et al. [42] (remission) | 34.3 | 35.9 | 32.3 | 33.5 | 32.5 | 37.6 | 38.7 | 45.2 |
Valassi et al. [47] (placebo) | 63.8 | 68.8 | 63.1 | 38.8 | 26.9 | 65.6 | 62.5 | 55 |
Valassi et al. [47] (GH) | 80.6 | 58.3 | 76.4 | 61.7 | 28.9 | 70.8 | 77.8 | 65.3 |
Average score | 70.6 | 66.2 | 68.1 | 57.1 | 46.4 | 75.0 | 72.9 | 67.5 |
Cushing’s disease
Active/naïve patient groups
PF | PR | Pain | GH | Vit | SF | ER | MH | |
---|---|---|---|---|---|---|---|---|
Milian et al. [62] (preoperative) | 9.6 | 21.6 | 24.9 | 12.1 | 9.8 | 12.4 | 22.1 | 13 |
Johnson et al. [31] (active) | 36.6 | 36.1 | 40.8 | 36.4 | 35.4 | 35 | 38.8 | 38.4 |
Psaras et al. [42] (no remission) | 37.6 | 25 | 44.6 | 39.7 | 47.2 | 31.6 | 26 | 43.8 |
Lindsay et al. [53] (pre-surgery) | 28.3 | 31.8 | 41.9 | 34.4 | 36.4 | 29.8 | 36.6 | 39.7 |
Van der Pas et al. [48] (untreated) | 54.4 | 33.6 | 75.3 | 45.6 | 59.4 | 60.4 | ||
Average score | 33.3 | 29.6 | 45.5 | 33.6 | 32.2 | 33.6 | 36.8 | 33.7 |
Controlled/treated patient groups
PF | PR | Pain | GH | Vit | SF | ER | MH | |
---|---|---|---|---|---|---|---|---|
Lindsay et al. [53] (remission) | 45.5 | 45.7 | 47.4 | 44.2 | 46.5 | 47.2 | 45.6 | 47.3 |
Lindsay et al. [53] (after surgery) | 45.9 | 45.9 | 48.6 | 48.1 | 48.3 | 46.7 | 49 | 51.4 |
Van Aken et al. [54] (remission) | 68 | 65 | 73 | 54 | 73 | 67 | ||
Tiemensma et al. [23] (remission) | 63.5 | 51.3 | 69.6 | 50.1 | 48.6 | 72.1 | 62.7 | 61.4 |
Milian et al. [62] (12 months after surgery) | 41.9 | 39.5 | 43 | 37.5 | 32 | 40.5 | 42.9 | 52.1 |
Psaras et al. [42] (remission) | 43.3 | 40.1 | 38.3 | 31.6 | 36.9 | 32.9 | 58.3 | 40.7 |
Hawn et al. [51] (after adrenalectomy) | 65 | 39 | 52 | 44 | 30 | 53 | 43 | 58 |
Smith et al. [56] (after adrenalectomy) | 48.5 | 45.4 | 50.1 | 42.5 | 41.8 | 45.1 | 48.9 | 46.6 |
Average score | 52.7 | 46.5 | 52.8 | 44.0 | 40.6 | 51.3 | 52.2 | 51.1 |
Rights and permissions
About this article
Cite this article
Andela, C.D., Scharloo, M., Pereira, A.M. et al. Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary 18, 752–776 (2015). https://doi.org/10.1007/s11102-015-0636-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-015-0636-7